Eli Lilly: positive results from weekly insulin trials

(CercleFinance.com) - Eli Lilly announces "positive" results from two phase 3 clinical trials (QWINT-1 and QWINT-3) evaluating weekly administration of insulin efsitora alfa in adults with type 2 diabetes compared to daily administration of basal insulins.


The results showed that efsitora is as effective as daily insulin in reducing HbA1c, with a similar safety profile and fewer episodes of hypoglycaemia.

Efsitora could simplify insulin management with a weekly regimen, making life easier for patients. Detailed results will be presented at forthcoming conferences.


Copyright (c) 2024 CercleFinance.com. All rights reserved.